5-Amino-1MQ vs NA-931
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
First, a correction worth making loudly: 5-amino-1MQ is not a peptide. It is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. It blocks an enzyme called NNMT, and in obese mice it produced weight and fat loss without the animals eating less. No human trials have been published.
Also: Bioglutide, cyclic glycine-proline
NA-931 (Bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of IGF-1. Its developer, Biomed Industries, describes it as an oral once-daily agonist at four receptors at once - IGF-1, GLP-1, GIP and glucagon - and has reported 13 to 15 percent weight loss in a 126-person Phase 2 trial. Those numbers have only ever appeared in conference abstracts, never in a peer-reviewed paper, and no trial results have been filed to ClinicalTrials.gov. The same molecule is already sold as a consumer brain-health supplement and as a Sigma-Aldrich catalogue chemical, which makes it unusually cheap to source and unusually hard to verify.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- NA-931 has stronger research evidence (Phase II Completed, Unpublished) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | 5-Amino-1MQ | NA-931 |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NNMT (nicotinamide N-methyltransferase) takes nicotinamide and tags it with a methyl group borrowed from SAM, the cell's main methyl donor, producing 1-methylnicotinamide. In fat tissue, high NNMT activity is thought to drain both NAD+ precursors and SAM, nudging cells toward storing fat. The hypothesis behind 5-amino-1MQ is straightforward: inhibit NNMT, and you preserve NAD+ and SAM inside adipocytes, which shifts them away from fat storage and toward burning energy. The published mouse work showed NNMT inhibition raising intracellular NAD+ and SAM, consistent with that idea. It is a plausible, well-reasoned mechanism, but in humans it remains a hypothesis, not a demonstrated effect. | Cyclic glycine-proline is a diketopiperazine: glycine and proline joined into a small ring, 154 daltons, roughly a thirtieth the size of tirzepatide or retatrutide. The independent literature, mostly from Jian Guan's group in Auckland, describes a single mechanism: cGP competes with IGF-1 for binding to IGFBP-3, which frees up IGF-1 that was otherwise bound and inactive. That is a bioavailability effect, studied for stroke recovery, Parkinson's and blood pressure rather than for weight. Biomed's own patent filing (WO2025160184A1) goes much further, claiming the same molecule is a 'quadruple receptor agonist' at IGF-1, GLP-1, GIP and glucagon receptors. That claim is worth understanding properly, because it is the entire basis of the weight-loss story. GLP-1, GIP and glucagon receptors are class B GPCRs, the kind that normally need a thirty-plus residue peptide wrapping into the receptor's binding groove to switch on. A 154-dalton ring activating all three would be a genuinely significant pharmacological finding. No independent group has reported it. Searching PubMed for cyclic glycine-proline alongside GLP-1 returns nothing at all. |
| Common Dosing | 50-75 mg daily Once daily, morning | 120 mg daily, oral Once daily |
| Administration | Subcutaneous injection or oral | Oral capsule or tablet, once daily |
| Typical Duration | 4-6 weeks (cycling recommended) | 28 days in Phase 1, 13 weeks in Phase 2 |
| Best Time to Take | Morning, fasted | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The headline study (Neelakantan et al.) tested small-molecule NNMT inhibitors in diet-induced obese mice. Treated animals lost weight (roughly 5% from baseline over about 11 days in that work) and shed white adipose mass, with reduced circulating cholesterol and no change in food intake, which points to a metabolic effect rather than appetite suppression. That is genuinely interesting preclinical data. But here is the honest part: the entire evidence base is animal and cell studies. There are no published human clinical trials demonstrating that 5-amino-1MQ causes fat loss, raises energy expenditure, or is safe over time in people. Claims of specific human fat-loss percentages from vendors are not backed by trial data. Treat it as an early-stage research compound, not a proven product. | There are no peer-reviewed publications on NA-931. Not one. Everything in circulation is a conference abstract, and the abstracts carrying the efficacy numbers list Biomed's CEO as sole author with conflicts declared as 'None'. Two trials have completed, both run entirely in Australia: a 74-person Phase 1 (NCT06615700, completed September 2024) and a 126-person Phase 2 (NCT06564753, completed April 2025). Neither has results posted. A third trial (NCT06732245) would run in the US, Australia and New Zealand, but has not started recruiting. The reported weight loss is where this gets difficult. The same 126-person Phase 2 has been presented three times with three different numbers: 14.8 percent at ADA in June 2025, 13.8 percent at ENDO in July, and 13.8 percent with a different placebo-adjusted figure in a September press release. Enrolment is given as 125 in the abstracts against 126 on the registry. A result that moves between presentations is not yet a result. The company's website states NA-931 is in Phase 3. No Phase 3 trial for NA-931 is registered on ClinicalTrials.gov. The announcement traces to a single paid newswire release in January 2026, syndicated into around twenty local newspaper press-release sections, which reads like broad coverage but is one purchased placement. |
Frequently Asked Questions: 5-Amino-1MQ vs NA-931
What is the difference between 5-Amino-1MQ and NA-931?
5-Amino-1MQ is a weight loss peptide that first, a correction worth making loudly: 5-amino-1mq is not a peptide. it is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. it blocks an enzyme called nnmt, and in obese mice it produced weight and fat loss without the animals eating less. no human trials have been published. NA-931 is a weight loss peptide that na-931 (bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of igf-1. its developer, biomed industries, describes it as an oral once-daily agonist at four receptors at once - igf-1, glp-1, gip and glucagon - and has reported 13 to 15 percent weight loss in a 126-person phase 2 trial. those numbers have only ever appeared in conference abstracts, never in a peer-reviewed paper, and no trial results have been filed to clinicaltrials.gov. the same molecule is already sold as a consumer brain-health supplement and as a sigma-aldrich catalogue chemical, which makes it unusually cheap to source and unusually hard to verify. The main differences lie in their mechanisms of action and clinical applications.
Which is better, 5-Amino-1MQ or NA-931?
Neither is universally "better" - the choice depends on your specific goals. 5-Amino-1MQ is typically used for weight loss purposes, while NA-931 is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can 5-Amino-1MQ and NA-931 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using 5-Amino-1MQ and NA-931 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.